ATE352617T1 - Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper - Google Patents

Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper

Info

Publication number
ATE352617T1
ATE352617T1 AT95920125T AT95920125T ATE352617T1 AT E352617 T1 ATE352617 T1 AT E352617T1 AT 95920125 T AT95920125 T AT 95920125T AT 95920125 T AT95920125 T AT 95920125T AT E352617 T1 ATE352617 T1 AT E352617T1
Authority
AT
Austria
Prior art keywords
lag
protein
antidiotypical
antibodies
soluble polypeptide
Prior art date
Application number
AT95920125T
Other languages
English (en)
Inventor
Florence Faure
Thierry Hercend
Bertrand Huard
Frederic Triebel
Original Assignee
Roussy Inst Gustave
Inst Nat Sante Rech Med
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Inst Nat Sante Rech Med, Applied Research Systems filed Critical Roussy Inst Gustave
Application granted granted Critical
Publication of ATE352617T1 publication Critical patent/ATE352617T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95920125T 1994-05-06 1995-05-05 Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper ATE352617T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9405643 1994-05-06

Publications (1)

Publication Number Publication Date
ATE352617T1 true ATE352617T1 (de) 2007-02-15

Family

ID=9463004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95920125T ATE352617T1 (de) 1994-05-06 1995-05-05 Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper

Country Status (18)

Country Link
US (3) US5955300A (de)
EP (1) EP0758383B1 (de)
JP (1) JP3700859B2 (de)
KR (1) KR100257466B1 (de)
CN (1) CN1110557C (de)
AT (1) ATE352617T1 (de)
BR (1) BR9507618A (de)
CA (1) CA2189657C (de)
DE (1) DE69535375T2 (de)
DK (1) DK0758383T3 (de)
ES (1) ES2281899T3 (de)
IL (1) IL113617A (de)
MX (1) MX9605365A (de)
NO (1) NO325828B1 (de)
PT (1) PT758383E (de)
RU (1) RU2178306C2 (de)
WO (1) WO1995030750A2 (de)
ZA (1) ZA953629B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE227586T1 (de) 1995-07-21 2002-11-15 Applied Research Systems Verfahren zur erkennung, identifizierung, isolierung, selektiver markierung und zielgerichteter erkennung von th1 lymphozyten mit hilfe von lag-3 protein
CA2273080C (fr) * 1996-11-28 2004-11-09 Institut Gustave Roussy Mutants de la proteine lag-3, leur expression et utilisation
PT941329E (pt) * 1996-11-29 2004-11-30 Applied Research Systems Metodo para prevenir a rejeicao de enxertos em transplantacao e para produzir uma celula-hospedeiro para terapia genetica universal utilizando activacao de linfocitos (lag-3)
EP0900841A1 (de) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Spleissvarianten von LAG-3
EP0893507A1 (de) 1997-07-25 1999-01-27 Institut Gustave Roussy Verwendung von MHC Klass II Liganden (CD4 und LAG-3) als Adjuvanz für Impfungen und von LAG-3 in der Behandlung von Krebs
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6434012B2 (en) * 2000-02-11 2002-08-13 Tyco Electronics Logistics Ag Circuit board interconnect
JP2003533187A (ja) * 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
WO2003072035A2 (en) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004078928A2 (en) † 2003-02-28 2004-09-16 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP2044949A1 (de) 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
SI3508502T1 (sl) 2013-09-20 2023-07-31 Bristol-Myers Squibb Company Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
EP3250250A4 (de) 2015-01-30 2019-05-22 President and Fellows of Harvard College Peritumorale und intratumorale materialien zur krebstherapie
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
HUE055207T2 (hu) 2015-07-30 2021-11-29 Macrogenics Inc PD-1 és LAG-3 kötõ molekulák és eljárások azok alkalmazására
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
AU2016358101B2 (en) * 2015-11-20 2022-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized Lymphocyte-activation gene 3
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
EA201891178A1 (ru) 2015-12-14 2019-01-31 Макродженикс, Инк. Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
WO2017136734A1 (en) * 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
TWI640536B (zh) 2016-06-20 2018-11-11 克馬伯有限公司 抗體
AU2017282892B2 (en) 2016-06-23 2023-10-26 Jiangsu Hengrui Medicine Co., Ltd. LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof
TW202436356A (zh) 2016-10-11 2024-09-16 美商艾吉納斯公司 抗ｌａｇ－３抗體及其使用方法
PE20190911A1 (es) 2016-10-13 2019-06-26 Symphogen As Composiciones y anticuerpos anti-lag-3
WO2018081329A1 (en) 2016-10-28 2018-05-03 Merck Sharp & Dohme Corp. Purification process for removal of tyrosine sulfation antibody variants; purified compositions
WO2018083087A2 (en) 2016-11-02 2018-05-11 Glaxosmithkline Intellectual Property (No.2) Limited Binding proteins
AU2018219909B2 (en) 2017-02-10 2025-02-27 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-LAG3 antibodies for immuno-PET imaging
CA3185303A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-a, tim-3, and lag-3
US11339218B2 (en) * 2017-05-10 2022-05-24 Zhejiang Shimai Pharmaceutical Co., Ltd. Human monoclonal antibodies against LAG3 and uses thereof
KR20240155979A (ko) 2017-05-30 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
KR102713203B1 (ko) 2017-05-30 2024-10-10 브리스톨-마이어스 스큅 컴퍼니 Lag-3 양성 종양의 치료
US11390679B2 (en) 2017-08-30 2022-07-19 Phanes Therapeutics, Inc. Anti-LAG-3 antibodies and uses thereof
WO2019120269A1 (zh) 2017-12-22 2019-06-27 江苏恒瑞医药股份有限公司 Lag-3抗体药物组合物及其用途
EP3969040A1 (de) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Kombination von pd-1-inhibitoren und lag-3-inhibitoren zur erhöhung der wirksamkeit bei der behandlung von krebs
CN115340606B (zh) * 2019-05-31 2023-12-19 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途
AU2021364837A1 (en) 2020-10-23 2023-05-25 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
KR20250155054A (ko) 2023-03-13 2025-10-29 리제너론 파마슈티칼스 인코포레이티드 흑색종 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2026035866A1 (en) 2024-08-07 2026-02-12 Iovance Biotherapeutics, Inc. Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with a lag-3 inhibitor and a pd-1 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325224B1 (de) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Verfahren zur Herstellung von sekretierten Rezeptoranalogen
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
CA2086325C (en) * 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods

Also Published As

Publication number Publication date
CN1110557C (zh) 2003-06-04
KR100257466B1 (ko) 2000-07-01
EP0758383B1 (de) 2007-01-24
DE69535375D1 (de) 2007-03-15
CA2189657C (fr) 2002-03-12
NO964650D0 (no) 1996-11-04
CN1155904A (zh) 1997-07-30
KR970702917A (ko) 1997-06-10
JPH09508023A (ja) 1997-08-19
US5955300A (en) 1999-09-21
MX9605365A (es) 1997-12-31
IL113617A0 (en) 1995-08-31
WO1995030750A8 (fr) 1999-07-29
JP3700859B2 (ja) 2005-09-28
AU708825B2 (en) 1999-08-12
RU2178306C2 (ru) 2002-01-20
US6143273A (en) 2000-11-07
WO1995030750A2 (fr) 1995-11-16
WO1995030750A3 (fr) 1995-12-21
IL113617A (en) 2007-09-20
EP0758383A1 (de) 1997-02-19
ZA953629B (en) 1996-11-05
BR9507618A (pt) 1997-08-19
DE69535375T2 (de) 2007-11-08
CA2189657A1 (fr) 1995-11-16
AU2570195A (en) 1995-11-29
NO325828B1 (no) 2008-07-28
NO964650L (no) 1997-01-06
ES2281899T3 (es) 2007-10-01
USRE38313E1 (en) 2003-11-11
PT758383E (pt) 2007-05-31
DK0758383T3 (da) 2007-05-29

Similar Documents

Publication Publication Date Title
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
PT662827E (pt) Metodos de diagnostico e composicoes farmaceuticas a base de proteinas notch e acidos nucleicos
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
NZ500253A (en) Osteoprotegerin binding proteins and receptors
HUT63652A (en) Process for producing cd44 surface protein variants, dna sequences encoding them and antibodies against them, as well as their application in diagnosis and therapy
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DE69926627D1 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
ATE223481T1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
AU7017494A (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
ATE190318T1 (de) Pcna bindende substanz
AU3850997A (en) Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines
ATE356831T1 (de) Neuer galaninrezeptor
ATE290088T1 (de) Verfahren zur spaltung eines chimeren proteins mittels eines 'processing'-enzyms
DE59105231D1 (de) Klonierung und Überexpression von Glucose-6-Phosphat-Dehydrogenase aus Leuconostoc dextranicus.
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
Schalekamp et al. Recombination of embryonic haemoglobin chains during the development of the chick
ATE76081T1 (de) Verfahren zur herstellung von dipeptiden mit nterminalen nichtproteinogenen aminosaeuren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0758383

Country of ref document: EP

EEIH Change in the person of patent owner